Eisenmenger's syndrome: In search of the best vasodilator

Cardiology (Switzerland)

Volumn 126, Issue 4, 2013, Pages 252-254

  Kuebler, Wolfgang M ^a,b,c,d  

^a ST MICHAEL'S HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^d DEUTSCHES HERZZENTRUM BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCHOLINE; ENDOTHELIN RECEPTOR ANTAGONIST; ILOPROST; VASODILATOR AGENT;

ARTERIAL OXYGEN SATURATION; CONGENITAL HEART DISEASE; EDITORIAL; EISENMENGER COMPLEX; ENDOTHELIAL DYSFUNCTION; HEART HEMODYNAMICS; HEART VENTRICLE SEPTUM DEFECT; HUMAN; LUNG ARTERY PRESSURE; LUNG RESISTANCE; LUNG VASCULAR RESISTANCE; META ANALYSIS (TOPIC); MUSCLE HYPERTROPHY; OXYGENATION; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); SMOOTH MUSCLE FIBER; SYSTEMATIC REVIEW (TOPIC); SYSTEMIC CIRCULATION; TREATMENT OUTCOME; VASOCONSTRICTION;

HEART SEPTAL DEFECTS, ATRIAL; HEART SEPTAL DEFECTS, VENTRICULAR; HUMANS; HYPERTENSION, PULMONARY; ILOPROST; VASODILATOR AGENTS;

EID: 84885026185     PISSN: 00086312     EISSN: 14219751     Source Type: Journal    
DOI: 10.1159/000354937     Document Type: Editorial

References (18)

1. Eisenmenger V: Die angeborenen Defekte der Kammerscheidewnde des Herzens. Z Klin Med 1897; 32: 1-28.
2. Wood P: Pulmonary hypertension with special reference to the vasoconstrictive factor. Br Heart J 1958; 20: 557-570.
3. Kerem A, Yin J, Kaestle SM, et al: Lung endothelial dysfunction in congestive heart failure: role of impaired Ca 2+ signaling and cytoskeletal reorganization. Circ Res 2010; 106: 1103-1116.
4. Rabinovitch M, Haworth SG, Castaneda AR, Nadas AS, Reid LM: Lung biopsy in congenital heart disease: a morphometric approach to pulmonary vascular disease. Circulation 1978; 58: 1107-1122.
5. Beghetti M, Galie N: Eisenmenger syndrome a clinical perspective in a new therapeutic era of pulmonary arterial hypertension. J Am Coll Cardiol 2009; 53: 733-740.
6. Miller OI, Tang SF, Keech A, Pigott NB, Beller E, Celermajer DS: Inhaled nitric oxide and prevention of pulmonary hypertension after congenital heart surgery: a randomised double-blind study. Lancet 2000; 356: 1464-1469.
7. Bizzarro M, Gross I: Inhaled nitric oxide for the postoperative management of pulmonary hypertension in infants and children with congenital heart disease. Cochrane Database Syst Rev 2005; 4:CD005055.
8. Hallioglu O, Dilber E, Celiker A: Comparison of acute hemodynamic effects of aerosolized and intravenous iloprost in secondary pulmonary hypertension in children with congenital heart disease. Am J Cardiol 2003; 92: 1007-1009.
9. Rimensberger PC, Spahr-Schopfer I, Berner M, et al: Inhaled nitric oxide versus aerosolized iloprost in secondary pulmonary hypertension in children with congenital heart disease: vasodilator capacity and cellular mechanisms. Circulation 2001; 103: 544-548.
10. Limsuwan A, Wanitkul S, Khosithset A, Attanavanich S, Samankatiwat P: Aerosolized iloprost for postoperative pulmonary hypertensive crisis in children with congenital heart disease. Int J Cardiol 2008; 129: 333-338.
11. Gorenflo M, Gu H, Xu Z: Peri-operative pulmonary hypertension in paediatric patients: current strategies in children with congenital heart disease. Cardiology 2010; 116: 10-17.
12. Sung KW, Jeon YB, Kim NY, et al: The effects of perioperative inhaled iloprost on pulmonary hypertension with congenital heart disease. Cardiology 2013;126:224-229.
13. Birukova AA, Fu P, Xing J, Cokic I, Birukov KG: Lung endothelial barrier protection by iloprost in the 2-hit models of ventilator-induced lung injury (VILI) involves inhibition of Rho signaling. Transl Res 2010; 155: 44-54.
14. Kemming G, Kisch-Wedel H, Flondor M, et al: Improved ventricular function during inhalation of PGI 2 aerosol partly relies on enhanced myocardial contractility. Eur Surg Res 2005; 37: 9-17.
15. Levy M, Maurey C, Celermajer DS, et al: Impaired apoptosis of pulmonary endothelial cells is associated with intimal proliferation and irreversibility of pulmonary hypertension in congenital heart disease. J Am Coll Cardiol 2007; 49: 803-810.
16. Boeck L, Tamm M, Grendelmeier P, Stolz D: Acute effects of aerosolized iloprost in COPD related pulmonary hypertension - a randomized controlled crossover trial. PLoS One 2012; 7:e52248.
17. Salehian O, Schwerzmann M, Rambihar S, et al: Left ventricular dysfunction and mortality in adult patients with Eisenmenger syndrome. Congenit Heart Dis 2007; 2: 156-164.
18. Yin N, Kaestle SM, Kuppe H, Kuebler WM: Iloprost inhalation causes lung edema in overperfused heart failure lungs (abstract). Am J Respir Crit Care Med 2009; 179:A3376.